Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis

Reviews in Gastroenterological Disorders

Volumn 8, Issue 1, 2008, Pages 22-32

  Lichtenstein, Gary R ^a   Rubin, David T ^b   Sabesin, Seymour M ^c   Velayos, Fernando S ^d   Vitat, Philippe ^e  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Digestive Diseases Education Company   (United States)

Author keywords

Inflammatory bowel disease; Mesalamine; Treatment adherence; Ulcerative colitis

Indexed keywords

MESALAZINE; SALAZOSULFAPYRIDINE; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL TRIAL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; GENDER; HUMAN; PATIENT COMPLIANCE; PRESCRIPTION; RECURRENT DISEASE; REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; WELLBEING; RISK FACTOR; TREATMENT REFUSAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; HUMANS; MESALAMINE; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 41749100856     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15:79-94.
2. Bernklev T, Jahnsen J, Aadland E, et al; IBSEN Study Group. Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. Scand J Gastroenterol. 2004;39:365-373.
3. Janke KH, Klump B, Gregor M, et al. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:272-286.
4. Kombluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385.
5. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007;13:254-261.
6. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
7. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000543.
8. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000544.
9. Svartz N. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. Am J Gastroenterol. 1988;83:497-503.
10. Svartz N. Treatment of ulcerative colitis with salazopyrin. Int Surg. 1968;50:421-427.
11. Azad Khan AK, Howes DT, Piris J, Truelove SC. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut. 1980;21:232-240.
12. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977;2:892-895.
13. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972;181:555-562.
14. Das KM, Eastwood MA, McManus JP, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973;289:491-495.
15. Taffet SL, Das KM. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci. 1983;28:833-842.
16. Sharma BK. Safety profile of the new 5-ASA based compound. Can J Gastroenterol. 1990;4:443-445.
17. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalkylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004;19:179-189.
18. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95:1263-1276.
19. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med. 1991;115:350-355.
20. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993;88:1188-1197.
21. Levine DS, Riff DS, Pruitt R, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002;97:1398-1407.
22. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100:2478-2485.
23. Hanauer SB, Sninsky CA, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. Ann Intern Med. 1996;124:204-211.
24. Hanauer SB. New lessons: classic treatments, expanding options in ulcerative colitis. Colorectal Dis. 2006;8(suppl 1):20-24.
25. Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND 1 trial. Can J Gastroenterol. 2007;21:827-834.
26. World Health Organization. Adherence to long-term therapies: evidence for action. Available at: http://www.emro.who.int/ncd/Publications/ adherence_report.pdf. Accessed January 31, 2008.
27. Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J. 1995;130(3 pt 1):572-579.
28. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMX. Inflamm Bowel Dis. 2005;11:421-427.
29. Kane S, Shaya F, Wong W, Joseph R. Compliance with 5-ASA products is associated with decreased medical costs [abstract]. Am J Gastroenterol. 2006;101(9 suppl):S436.
30. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929-2933.
31. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003;98:1535-1544.
32. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:191-198.
33. Loftus EV Jr. A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006;12:1107-1113.
34. van Hees PA, van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol. 1982;4:333-336.
35. Bernai I, Domenech E, Garcia-Planella E, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci. 2006;51:2165-2169.
36. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol. 2007;102:1417-1426.
37. Nigro G, Angelini G, Grosso SB, et al. Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol. 2001;32:66-68.
38. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2003;1:170-173.
39. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003; 114:39-43.
40. Kane S, Aikens J, Hanauer S. Medication regimens are associated with non-adherence in quiescent ulcerative colitis [abstract]. Am J Gastroenterol. 2002;98(9 suppl):S253.
41. Eaden JA, Abrams KK, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000;14:145-153.
42. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2005;100:1345-1353.
43. van Staa TP, Card T, Logan RF, Leufkens HG. 5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573-1578.
44. Han SW, McColl E, Barton JR, et al. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis. 2005;11:24-34.
45. Farup PG, Hinterleitner TA, Lukas M, et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis. 2001;7:237-242.
46. Shire US. Lialda (mesalamine) delayed-release tablets. Wayne, PA: Shire US; 2007.
47. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007;132:66-75.
48. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5:95-102.
49. Lichtenstein GR, Kamm MA, Karlstadt R, et al. MMX mesalamine is effective for the maintenance of ulcerative colitis remission in both left-sided and extensive disease [abstract]. Am J Gastroenterol. 2007;102:S462.
50. Panaccione R, Kamm MA, Karlstadt R, et al. Once- or twice-daily MMX mesalamine for the maintenance of remission of mild-to-moderate ulcerative colitis [abstract]. Am J Gastroenterol. 2007;102:S463.
51. Sandborn WJ, Karlstadt R, Barrett K, et al. MMX mesalamine is effective for the maintenance of remission in mild-to-moderate ulcerative colitis irrespective of patients' relapse history [abstract]. Am J Gastroenterol. 2007;102:S461.
52. Kruis W, Gorelov A, Kiudelis G, et al. Once daily dosing of 3g mesalamine (Salofalk granules) is therapeutic equivalent to a three-times daily dosing of 1g mesalamine for the treatment of active ulcerative colitis [abstract]. Gastroenterology. 2007;132:A130-A131.
53. Marteau P, Florent C. Comparative, open, randomized trial of the efficacy and tolerance of slow-release 5-ASA suppositories once daily versus conventional 5-ASA suppositories twice daily in the treatment of active cryptogenic proctitis. Am J Gastroenterol. 2000;95:166-170.